RTW-managed funds lift Kailera Therapeutics (KLRA) stake via buys, conversions
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
RTW Investments-managed funds, as ten percent owners of Kailera Therapeutics, reported increasing their indirect position in the company. On April 20, 2026, affiliated funds bought 500,000 shares of Common Stock in open-market transactions at $16.00 per share.
On the same date, all held Series A and Series B Preferred Stock automatically converted into Common Stock on a 1-for-1 basis for no additional consideration immediately before the closing of the initial public offering, adding 10,276,820 shares. After these conversions and purchases, the affiliated funds indirectly held 10,776,820 shares of Common Stock. The filing notes that RTW and Roderick Wong disclaim beneficial ownership except to the extent of their pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 500,000 shares ($8,000,000)
Net Buy
4 txns
Insider
RTW INVESTMENTS, LP, WONG RODERICK
Role
null | null
Bought
500,000 shs ($8.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Preferred Stock | 8,250,000 | $0.00 | -- |
| Conversion | Series B Preferred Stock | 2,026,820 | $0.00 | -- |
| Conversion | Common Stock | 10,276,820 | $0.00 | -- |
| Purchase | Common Stock | 500,000 | $16.00 | $8.00M |
Holdings After Transaction:
Series A Preferred Stock — 0 shares (Indirect, See footnote);
Series B Preferred Stock — 0 shares (Indirect, See footnote);
Common Stock — 10,276,820 shares (Indirect, See footnote)
Footnotes (1)
- Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date. Held by certain affiliated funds managed by RTW Investments, LP ("RTW"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
Key Figures
Open-market purchase: 500,000 shares at $16.00
Total common after transactions: 10,776,820 shares
Preferred conversion total: 10,276,820 shares
+2 more
5 metrics
Open-market purchase
500,000 shares at $16.00
Common Stock bought on April 20, 2026
Total common after transactions
10,776,820 shares
Indirectly held by RTW-affiliated funds following Form 4 transactions
Preferred conversion total
10,276,820 shares
Common Stock received from Series A and B Preferred automatic conversion
Series A Preferred converted
8,250,000 shares
Underlying Common Stock from Series A Preferred automatic conversion
Series B Preferred converted
2,026,820 shares
Underlying Common Stock from Series B Preferred automatic conversion
Key Terms
open-market purchase, derivative conversion, Series A Preferred Stock, Series B Preferred Stock, +1 more
5 terms
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
derivative conversion financial
"transaction_action": "derivative conversion""
Series A Preferred Stock financial
""security_title": "Series A Preferred Stock""
Series A preferred stock is a type of ownership share in a company that gives investors certain advantages, such as priority in receiving profits or getting their money back if the company is sold or goes bankrupt. It is often issued during early funding stages to attract investors by offering more security than common shares. This stock matters to investors because it provides a safer way to invest while still holding potential for future gains.
Series B Preferred Stock financial
""security_title": "Series B Preferred Stock""
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Section 16 regulatory
"beneficial ownership of the reported securities for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider activity did RTW Investments report for Kailera Therapeutics (KLRA)?
RTW-managed funds reported converting preferred stock into Common Stock and buying additional shares. They purchased 500,000 Common shares at $16.00 each and converted Series A and B Preferred Stock into 10,276,820 Common shares, increasing their indirect holdings.
What preferred stock did Kailera Therapeutics (KLRA) insiders convert into Common Stock?
Affiliated funds converted both Series A Preferred Stock and Series B Preferred Stock into Common Stock. The conversion occurred automatically on a 1-for-1 basis for no additional consideration immediately before the closing of the company’s initial public offering.
How do RTW Investments and Roderick Wong describe their ownership of Kailera Therapeutics (KLRA) shares?
The filing states that the reported Kailera Therapeutics securities are held by affiliated funds managed by RTW Investments, LP. It notes that RTW and Roderick Wong disclaim beneficial ownership of these securities for Section 16 purposes, except to the extent of their pecuniary interest.